Showing papers by "Yoon Keun Kim published in 2020"
Patent•
27 May 2020
TL;DR: In this paper, the authors proposed a composition comprising vesicles derived from Klebsiella pneumoniae and/or vesicle derived from Staphylococcus aureus as active components.
Abstract: The present invention relates to a composition comprising vesicles derived from Klebsiella pneumoniae and/or vesicles derived from Staphylococcus aureus as active components. More specifically, the present invention relates to an anti-cancer agent sensitivity enhancing use of the vesicles. Vesicles derived from Klebsiella pneumoniae or vesicles derived from Staphylococcus aureus are expected to minimize side effects and improve treatment efficiency in the treatment of various cancers.
Patent•
25 Jun 2020TL;DR: In this article, a method for diagnosing ovarian cancer through microbial metagenome analysis was proposed. But this method is not suitable for the detection of ovarian cancer in the early stages of the disease.
Abstract: The present invention relates to a method for diagnosing ovarian cancer through microbial metagenome analysis and, more specifically, to a method for performing metagenomic analysis by using a sample derived from a subject so as to analyze increases and decreases in the amount of extracellular vesicles derived from specific bacteria or archaea, thereby diagnosing ovarian cancer. The extracellular vesicles secreted from microbes present in the environment are absorbed into the body so as to directly influence the occurrence of cancer, and since early diagnosis of ovarian cancer before symptoms occur is difficult, effective treatment has been difficult. Through the metagenome analysis using a human-derived sample, according to the present invention, the risk of onset of ovarian cancer can be predicted in advance such that ovarian cancer risk groups are diagnosed and predicted in an early stage, thereby enabling the time of onset of the disease to be delayed or the onset of the disease to be prevented through appropriate management, and early diagnosis is enabled even after the onset of the disease, thereby enabling the incidence of ovarian cancer to be lowered and therapeutic effects to be increased.